LAKANA , a Cluster-randomized, Double-blinded, Parallel Group, Controlled Trial, Testing the Effects of Mass Drug Administration of Azithromycin on Mortality and Other Outcomes Among 1-11 Month Old Infants in Rural Mali.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 04 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azithromycin (Primary)
Indications Malaria
Focus Therapeutic Use
Acronyms LAKANA

Most Recent Events

31 Jan 2025 Status changed from active, no longer recruiting to completed.
28 Nov 2023 Planned primary completion date changed from 30 Jun 2024 to 31 Dec 2024.
15 Nov 2023 According to Trial design and Statistical analysis plan published in the Trials, enrollment for this trial began on 15 Oct 2020, and ended in Dec 2022. Data collection is ongoing and the last follow-up for the final participants is currently planned to take place in the second half of 2024. Also, an estimate the interim analysis to take place in August 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight